Proteomics: Applications and opportunities in preclinical drug development

Advances in DNA sequencing and the near-term availability of whole genome s equences for several pharmaceutically relevant organisms promise to dramati cally alter the breadth and scale of high-throughput proteomic studies. The substantial amount of literature is available in the public domain, demons trate the potential of proteomics in the preclinical phases of pharmaceutic al development. Over the next few years, it is anticipated that functional genomics and proteomics will have major impacts on the clinical phases of d rug development. Expected benefits are earlier proof-of-concept studies in man and increased efficiency of clinical trials through the availability of biologically relevant markers for drug efficacy and safety.